Unicycive Therapeutics, Inc. (UNCY)
| Market Cap | 190.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.89M |
| Shares Out | 26.70M |
| EPS (ttm) | -2.11 |
| PE Ratio | n/a |
| Forward PE | 3.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,420,398 |
| Open | 8.22 |
| Previous Close | 8.21 |
| Day's Range | 6.75 - 8.43 |
| 52-Week Range | 3.71 - 8.74 |
| Beta | 1.73 |
| Analysts | Strong Buy |
| Price Target | 41.30 (+479.24%) |
| Earnings Date | Aug 13, 2026 |
About UNCY
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for UNCY stock is "Strong Buy." The 12-month stock price target is $41.3, which is an increase of 479.24% from the latest price.
News
Unicycive Therapeutics Proxy statement: Proxy filing
Unicycive Therapeutics filed a proxy statement on June 22, 2026, providing details for shareholder voting and corporate governance matters.
Unicycive Therapeutics files $150M mixed securities shelf
16:18 EDT Unicycive Therapeutics (UNCY) files $150M mixed securities shelf
Unicycive Therapeutics Registration statement: Registration filing
Unicycive Therapeutics filed a registration statement on June 5, 2026, providing details about a securities offering with the SEC.
Unicycive Therapeutics Slides: Corporate presentation
Unicycive Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Unicycive Therapeutics price target raised to $18 from $15 at Benchmark
Benchmark raised the firm’s price target on Unicycive Therapeutics (UNCY) to $18 from $15 and keeps a Speculative Buy rating on the shares. The firm updated assumptions, but notes that…
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics Earnings release
Unicycive Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
Unicycive Therapeutics management to meet virtually with Piper Sandler
Virtual Meeting to be held on May 29 hosted by Piper Sandler.
Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $37 from $40 and keeps a Buy rating on the shares. The firm trimmed its target,…
Unicycive Therapeutics Slides: Company presentation
Unicycive Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)
“As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,” said…
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Therapeutics initiated with a Buy at B. Riley
B. Riley initiated coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $22 price target The firm says the investment thesis focuses on oxylanthanum carbonate, the company’s next generation...
Unicycive Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Upcoming PDUFA for oxylanthanum carbonate could enable a differentiated, low pill burden therapy for hyperphosphatemia in dialysis patients, with strong clinical data and a focused commercialization plan. Financial runway and reimbursement strategies support near-term launch.
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co...
Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark
Benchmark lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $21 and keeps a Speculative Buy rating on the shares. After having updated the firm’s share count…
Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim
Guggenheim lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $40 from $46 and keeps a Buy rating on the shares. The firm made “relatively modest adjustments” to its…